Circulating DNA to detect leftover disease after chemoradiotherapy for advanced head and neck cancer
Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma
NA · Centre Jean Perrin · NCT07178847
This trial will test whether a blood test for circulating tumor DNA can find leftover cancer three months after chemoradiotherapy in people with locally advanced head and neck squamous cell carcinoma enrolled in Neck-TAR.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 59 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Centre Jean Perrin (other) |
| Locations | 3 sites (Clermont-Ferrand, Puy-de-Dôme and 2 other locations) |
| Trial ID | NCT07178847 on ClinicalTrials.gov |
What this trial studies
This ancillary interventional study collects blood samples at one and three months after the end of chemoradiotherapy to measure circulating tumor DNA (cDNA). Participants are drawn from the ongoing Neck-TAR cohort and provide additional informed consent for the cDNA sampling. Researchers will compare cDNA detection at three months with clinical and radiological assessments of response to identify residual disease. The aim is to determine whether cDNA can serve as a minimally invasive biomarker to complement standard post-treatment surveillance.
Who should consider this trial
Good fit: Ideal candidates are adults with locally advanced head and neck squamous cell carcinoma who are already enrolled in the Neck-TAR study, have provided informed consent for the NeckTAR‑IN ancillary protocol, and are covered by the French social security system.
Not a fit: Patients not enrolled in Neck-TAR, those without detectable circulating tumor DNA shedding, or those with conditions that preclude follow-up imaging are unlikely to benefit from this ancillary protocol.
Why it matters
Potential benefit: If successful, the test could provide a noninvasive way to detect residual disease earlier or more accurately, helping guide follow-up and additional treatment decisions.
How similar studies have performed: Circulating tumor DNA approaches have shown promise in several cancer types and emerging, but not yet definitive, evidence supports their use for detecting residual disease in head and neck cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Selection Criteria: * Patient included in NeckTAR study * Written informed consent signed for NeckTAR-IN study * Affiliation to the French social security system
Where this trial is running
Clermont-Ferrand, Puy-de-Dôme and 2 other locations
- Centre Jean PERRIN — Clermont-Ferrand, Puy-de-Dôme, France (RECRUITING)
- Hôpital de la Croix-Rousse — Lyon, France (RECRUITING)
- CHU de Saint-Étienne — Saint-Etienne, France (RECRUITING)
Study contacts
- Study coordinator: Angeline GINZAC COUVÉ Project manager, PhD
- Email: angeline.ginzac@clermont.unicancer.fr
- Phone: 0463663337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Locally Advanced Head and Neck Carcinoma, circulating DNA, residual disease